Close

Precursor lymphoid neoplasms

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Overview

Precursor lymphoid neoplasms, also called neoplasms of precursor T cells and B cells, or lymphoblastic lymphomas which is used to describe the predominantly lymph node-based disease. This group of diseases represents a family of cancerous lymphoid neoplasms which recapitulate the characteristics of early lymphoid precursors of B- or T-lineage in morphology and immunophenotype, respectively. More than 70% of patients are diagnosed as stage IV, which is due to the aggressive nature of the disease. Lymphoblastic lymphoma comprises only 2% of all non-Hodgkin lymphomas (NHLs) in America, among which, 80 - 90% is T-Cell origin and the remainder part is B-cell phenotype. Congenital or acquired immunosuppression, and exposure to insecticide or high level of radiation are the most possible causes of the disease.

Signs, symptoms and treatments

The patients suffering from gross lymphadenopathy usually have impaired immunity, which leads to opportunistic infections and adjacent tissues getting compressed. In some cases, the lymphoblasts spread into central nervous system (CNS) or bone marrow, and in the later situation, it causes hematopoiesis dysfunction. However, combination chemotherapy can make a beautiful outcome with the help from supportive medications to control side effect and infection.

Loading...
Products
Global Services
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.